The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition [1]. It is also indicated for adolescents aged 12 and older with obesity and body weight above 60 kg (132 lbs) [1].
When Will a Wegovy Pill Be Available?
While Wegovy is currently administered as an injection, a once-daily oral formulation of semaglutide, known as Rybelsus, is approved for type 2 diabetes treatment [2]. However, there is no specific FDA approval for a pill form of Wegovy for weight management at this time.
How Does Wegovy Work for Weight Loss?
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the GLP-1 hormone, which is naturally released after eating [1]. It helps regulate appetite by increasing feelings of fullness and reducing hunger [1]. Wegovy is administered as a weekly subcutaneous injection [1].
What Are the Potential Side Effects of Wegovy?
Common side effects associated with Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and dizziness [1]. Serious side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and a risk of thyroid tumors [1].
How Does Wegovy Compare to Other Weight Loss Medications?
Wegovy's efficacy in clinical trials has demonstrated significant weight loss compared to placebo [1]. It is part of a class of drugs that target the GLP-1 pathway, which has shown effectiveness for weight management. Other medications in this class or with similar mechanisms may exist, each with their own specific approval criteria, efficacy, and side effect profiles.
What is the Cost and Insurance Coverage for Wegovy?
The cost of Wegovy can vary significantly, and insurance coverage may depend on the plan and specific medical necessity requirements [3]. Patients often explore options for financial assistance programs offered by manufacturers or through their healthcare providers.
What Are the Patent Expirations for Wegovy?
Information regarding specific patent expiration dates for Wegovy and its active ingredient, semaglutide, can be found on specialized pharmaceutical patent tracking resources [4]. These patents are crucial for understanding when generic versions might become available.
Who Manufactures Wegovy?
Wegovy is manufactured by Novo Nordisk [1].
Sources:
1. https://www.novonordisk.com/products/weight-management/wegovy.html
2. https://www.novonordisk.com/products/diabetes/rybelsus.html
3. https://www.wegovy.com/coverage-and-cost.html
4. https://drugpatentwatch.com/